Cara CDRM (Conduction Disturbance Risk Monitor) 2.0

Not Applicable

Active, not recruiting

• Conditions: Transcatheter Aortic Valve Replacement
• Interventions: Other: ECG monitoring for Conduction Disturbances

• Registration Number: NCT05465655
• Lead Sponsor: Cara Medical Ltd

Brief Summary

Prospective, multicenter, roll-in, pilot clinical trial.

Study subjects will be studied during the TAVR procedure and their 12 lead ECGs collected and analyzed for New-Onset Conduction Disturbances (NOCD).

The study will be conducted in two stages:

During the first roll-in stage of the study, 50 intended to undergo TAVR (all comers) will be enrolled.

Data will be collected according to the study schedule below of pre-, during and after the TAVR procedure up to 14 days FU.

This data for the first 50 patients will be analyzed to evaluate the ability of the Cara Monitor prediction of NOCD post TAVR.

The second stage of the stage will be conducted upon completion of the first stage analysis and will be considered to randomize 1:1 the subjects connected to Cara Monitor during the procedure versus site-specific current practice.

The effect of Cara Monitor on reduction of NOCD post TAVR compared to patients treated and followed per regular site-specific practice will be estimated.

Detailed Description

Data to be collected during the study procedure for both stages:

1. Pre-procedure:

1. Demographics, medical history, cardiac history, medications

2. Cardiac CT raw data to be collected from all the pre-procedure CT scans performed in Medical Centers and from out-of-hospital sources (if available).

3. In hospital 12 lead ECG

2. Procedure:

During the procedure, the 12 lead ECG will be recorded processed, and displayed on the Cara monitor that is connected to Norav NR-1207-3 ECG Holter System. The Hemodynamic and Fluoroscopy monitors will be recorded on a commercially available video recorder.

3. Post-procedure (in hospital)

1. After the procedure patients will continue to be connected to a commercially available to a commercially available 14 days ambulatory Holter monitor (AEM) (e.g. Bittium Faros™ ; MoMe™ Kardia) and will remain with the patient after the discharge for 14 days.

2. Hospital standard 12 lead ECG will be recorded after the procedure, downloaded and collected by the study team.

4. Post-procedure - out of hospital:

At discharge, patients will stay connected to the ambulatory Holter monitor (AEM) (Bittium Faros™; MoMe™ Kardia ) for 14 days post-procedure. Holter will be collected from patients at the end of the 14-day recording and its data downloaded and collected.

Patients will be followed according to the current medical practice.

5. Follow-up according to the current medical practice a. 30 days follow-up hospital visit: i. Cardiac echo (if available) ii. 12 lead ECG b. 6 month - Clinical FU phone call c. 12 months Clinical FU phone call

Conduction Disturbances (CD) outcome will be subdivided into:

1. PPM or High-Grade AV Block (HGAVB)

2. All other new onset (or deterioration) of CD that are not listed in #1

3. No new onset CD

Study Timeline

• Study First Submitted: 2022-07-15
• Study First Submitted QC: 2022-07-19
• Study First Posted: 2022-07-20
• Study Start: 2022-09-09
• Status Verified: 2023-08
• Last Update Submitted: 2024-07-31
• Last Update Posted: 2024-08-01
• Primary Completion: 2024-08-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Must meet be ≥ 18 years of age.
2. Must meet indications for TAVR using approved devices
3. Provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
4. Willing to comply with specified follow-up evaluations.
5. Must meet the legal minimum age to provide Informed Consent based on local regulatory requirements.

Exclusion Criteria

1. Any implanted device or an indication for treatment with rhythm management device (i.e., pacemaker, Cardiac Resynchronization Therapy (CRT) or Cardiac Resynchronization Therapy with cardioverter-defibrillator (CRT-D) at baseline.
2. Any contraindication to the TAVR procedure according to the instructions for use.
3. Less than the legal age of consent, legally incompetent, or otherwise vulnerable.
4. Planned treatment with any other investigational device, drug, or procedure (excluding registries) during the study period.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients undergoing TAVR	ECG monitoring for Conduction Disturbances	Study subjects will be studied during the TAVR procedure and their 12 lead ECGs collected and analyzed notifying for New-Onset Conduction Disturbances (NOCD) using Cara Monitor.

Primary Outcome Measures

Name	Time	Method
Evaluate Cara performance in reduction of New Onset Conduction Disturbances (NOCD)	14 days	Estimate the reduction of NOCD (percentage) at 14 days post TAVR while using Cara Monitor
Evaluate Cara performance in reduction of Permanent Pacemaker (PPM) or High-Grade AV Block (HGAVB)	14 days	Estimate the reduction (a percentage) of PPM or High-Grade AV Block (HGAVB)
Evaluate Cara usability using a dedicated questioner	1 Day of Procedure	Estimate learning curve of using CaraTM system (e.g. the experience required with system for achieving above improvements)
Evaluate Cara Safety, collecting Adverse Events	14 days	During the study patients will be followed for any adverse events relevant to the TAVR procedure as defined in the CRF

Trial Locations

Locations (1)

Mackram F. Eleid, M.D.; 🇺🇸 Rochester, Minnesota, United States